New tests could predict if breast cancer therapy is working

NCT ID NCT06067503

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is looking for better ways to see if endocrine therapy is working in people with a type of breast cancer called metastatic invasive lobular carcinoma. Researchers will use a special PET scan and blood tests to measure changes in estrogen signaling after 4 weeks of treatment. The goal is to find early signs of resistance, so doctors can adjust treatment sooner. Only 8 participants are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-fluorofuranylnorprogesterone (FFNP) and liquid biopsy
What this could lead to: If successful, this could lead to a way to quickly tell if endocrine therapy is working, helping doctors switch treatments sooner for patients with metastatic lobular breast cancer.
What could go wrong: This is a very small pilot study with only 8 participants, so results may not apply to everyone. It is designed to gather information, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast lobular carcinoma breast neoplasm Carcinoma, Lobular invasive lobular breast carcinoma metastatic malignant neoplasm Neoplasm Metastasis Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER LOBULAR BREAST CARCINOMA METASTATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

UW Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.